Tiloronum and α2b-inteferon in the treatment of cervical intraepithelial neoplasia i-ii with lesions of the vaginal fornix and walls

Authors

  • Н. Ф. Лигирда National Cancer Institute of the NAM S of Ukraine
  • В. С. Свінцицький National Cancer Institute of the NAM S of Ukraine
  • Н. П. Цип National Cancer Institute of the NAM S of Ukraine
  • С. В. Неспрядько National Cancer Institute of the NAM S of Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2015.22.25-28

Keywords:

epithelial dysplasia of the cervix, α2b-interferon, tiloronum, Lavomax

Abstract

In the study participated 62 patients with сervical intraepithelial neoplasia (CIN) with extension to the fornix and walls of vagina. At the stage of etiological treatment the patients were divided into 2 equal groups: group A (31 patients) – 18 patients with CIN II and 13 patients with CIN I, group B (31 patients) – 18 patients with CIN II and 13 patients with CIN I. In group А patients were prescribed a standard therapy α2b-interferon 500 000 IU suppositories twice a day every day for 14 days, and 125 mg of Tiloronum every 48 hours N10. In group В patients were prescribed a standard therapy α2b-interferon 500 000 IU suppositories twice a day every day for 14 days.

Assessment of colposcopic features in patients with CIN I-II after treatment showed that patients from the study group significantly more often (48.4%) compared with control group (12.9%) had a reduction of the affected area and displacement of the boundaries of CIN from walls of vagina to the cervix

Author Biographies

Н. Ф. Лигирда, National Cancer Institute of the NAM S of Ukraine

PhD, senior researcher at the Gynecologic Oncology Department

В. С. Свінцицький, National Cancer Institute of the NAM S of Ukraine

MD, Head of the Gynecologic Oncology Department

Н. П. Цип, National Cancer Institute of the NAM S of Ukraine

MD, senior researcher at the Gynecologic Oncology Department

С. В. Неспрядько, National Cancer Institute of the NAM S of Ukraine

PhD, senior researcher at the Gynecologic Oncology Department

References

Vorobiova, L.I., Lyhyrda, N.M. “Comparison of the therapeutic efficacy of different dosage forms of the drug alpha-2-interferon in patients with CIN I and CIN II.” Women Health, 5(51) (2010): 42–46.

Kasatkin, E.V. The validity and therapy effectiveness of subclinical and latent forms of human papillomavirus infection caused by a virus with high oncogenic risk. 3rd All-Russian Congress of Dermatologists: Abstracts. Moscow (2009): 82.

Clinical recommendations. Dermatovenereology. Ed. by A.A. Kubanova. Moscow. DEKS-Press (2007): 428 p.

Kasikhina, E.I. “Recurrent genital warts and latent HPV infection in women: risk factors, clinical features and treatment.” Clin Dermatol Venereology, 1(2011): 49–54.

Lyhyrda, N.F., Vorobiova, L.I., Krotevych, M.S. “Features of colposcopic diagnosis of precancer and early forms of cervical cancer.” Clinical Oncology, 1(2011): 56–60.

Lyhyrda, N.F., Vorobiova, L.I. “Clinical and laboratory study of complex treatment of cervical intraepithelial neoplasia.” Women's Health, 4(12) (2002): 23–27.

Order of the MOH of Ukraine of 02.04.2014 №236 “On approval and introduction of medical and technological documents on standardization of medical care in dysplasia and cervical cancer.”

Patent (UA ) Vorobiova, L.I., Lyhyrda, N.F., Vorontsov, A.L., Vinnytska, A.B. A method for treating precancerous cervical pathology caused by human papilloma virus / (Ukraine); Oncology Institute of the National Academy of Medical Sciences of Ukraine. № 52344 A. Ukraine. 6МПК A 61 K 38/21; Statement 11.04.2002. Bull. №12.

Published

2015-04-14

Issue

Section

Gynecology